Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer

Yuan,Yuan; Shen,Ning; Yang,Shu‑Yan; Zhao,Ling; Guan,Yong‑Mei

doi:10.3892/ol.2015.3177

Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer

Authors:
- Yuan Yuan
- Ning Shen
- Shu‑Yan Yang
- Ling Zhao
- Yong‑Mei Guan
View Affiliations

Affiliations: Department of Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Pathophysiology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, P.R. China, Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 6, 2015 https://doi.org/10.3892/ol.2015.3177
Pages: 342-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Extracellular matrix metalloproteinase inducer (CD147) and matrix metalloproteinase‑2 (MMP‑2) have been documented in various malignancies. CD147 is a member of the immunoglobulin superfamily, which promotes the production and release of MMPs in mesenchymal cells and tumor cells. MMP‑2 has been extensively studied and is considered to be particularly important in cancer invasion and metastasis. However, studies investigating the expression and prognostic value of CD147 in endometrioid endometrial carcinoma (EEC) are limited. The present study analyzed the expression of CD147 and MMP‑2 by immunohistochemistry in endometrial tissue samples from 107 patients with EEC and 30 patients with benign uterus myoma. The association between CD147 and MMP‑2 expression and clinicopathological characteristics was evaluated. The results showed that the overexpression of MMP‑2 was significantly associated with International Federation of Gynecology and Obstetrics stage (P=0.007), depth of invasion (P=0.037) and reduced expression of progesterone receptor (P=0.005). Kaplan‑Meier analyses indicated that CD147 overexpression alone (P<0.05 for disease‑specific survival) or in combination with MMP‑2 (P<0.001 for disease‑specific survival) was correlated with adverse prognosis in EEC patients. Multivariate analysis revealed that the combined overexpression of CD147 and MMP‑2 was an independent prognostic factor for disease‑specific survival (hazard ratio=5.141, P=0.001) in EEC patients. CD147 and MMP‑2 overexpression was positively correlated with aggressive phenotypic features in EEC, however it was negatively correlated with hormone receptor expression. The combination of CD147 and MMP‑2 overexpression in EEC further distinguished a subgroup of patients with poor prognosis. Thus, the results of present study indicate that the co‑expression of CD147 and MMP‑2 may be an independent prognostic factor in EEC patients.

View Figures

View References

1	Cancer statistics. JAMA. 310:9822013. View Article : Google Scholar : PubMed/NCBI
2	Fowler W and Mutch D: Management of endometrial cancer. Womens Health (Lond Engl). 4:479–489. 2008. View Article : Google Scholar : PubMed/NCBI
3	Millimaggi D, Mari M, D'Ascenzo S, et al: Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 9:349–357. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sidhu SS, Mengistab AT, Tauscher AN, LaVail J and Basbaum C: The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene. 23:956–963. 2004. View Article : Google Scholar : PubMed/NCBI
5	Garg K, Leitao MM Jr, Wynveen CA, et al: p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 23:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
6	Davidson B, Goldberg I, Berner A, et al: EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 20:161–169. 2003. View Article : Google Scholar : PubMed/NCBI
7	Tsai WC, Chao YC, Sheu LF, et al: EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS. 115:929–938. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zheng HC, Takahashi H, Murai Y, et al: Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
9	Zhong WD, Liang YX, Lin SX, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer. 130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
10	Yu W, Liu J, Xiong X, et al: Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 205:709–715. 2009. View Article : Google Scholar : PubMed/NCBI
11	Klein CA, Seidl S, Petat-Dutter K, et al: Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 20:387–392. 2002. View Article : Google Scholar : PubMed/NCBI
12	Wu W, Wang R, Liu H, et al: Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry. Med Oncol. 26:117–123. 2009. View Article : Google Scholar : PubMed/NCBI
13	Morris PC, Anderson JR, Anderson B and Buller RE: Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol. 56:406–411. 1995. View Article : Google Scholar : PubMed/NCBI
14	Kleine W, Maier T, Geyer H and Pfleiderer A: Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 38:59–65. 1990. View Article : Google Scholar : PubMed/NCBI
15	Pertschuk LP, Masood S, Simone J, et al: Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 63:28–33. 1996. View Article : Google Scholar : PubMed/NCBI
16	Deen S: FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol. 28:477–478. 2009. View Article : Google Scholar : PubMed/NCBI
17	Horn LC, Schmidt D, Fathke C and Ulrich U: Mitglieder der Organgruppe Uterus der AGO: New FIGO staging for uterine sarcomas. Pathologe. 30:302–303. 2009.(In German). PubMed/NCBI
18	Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 12:1707–1714. 2006. View Article : Google Scholar : PubMed/NCBI
19	Gou XX, Jin F, Chen HX, Wu WL, Chen L and Zeng Y: Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and clinical significance. Zhonghua Yi Xue Za Zhi. 90:1264–1267. 2010.(In Chinese). PubMed/NCBI
20	Wang S, Li B, Wang S, Li Y and Li J: Expression and clinical significance of CD147 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lungs. Zhongguo Fei Ai Za Zhi. 14:710–714. 2011.(In Chinese). PubMed/NCBI
21	Tan H, Ye K, Wang Z and Tang H: Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol. 38:528–533. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kanekura T and Chen X: CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
23	Xue YJ, Lu Q and Sun ZX: CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol. 28:1363–1372. 2011. View Article : Google Scholar : PubMed/NCBI
24	Rosenthal EL, Shreenivas S, Peters GE, et al: Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope. 113:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
25	Tan H, Ye K, Wang Z and Tang H: CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl Res. 152:143–149. 2008. View Article : Google Scholar : PubMed/NCBI
26	Zhao L, Yu N, Guo T, et al: Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 23:1047–1054. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yang JM, Xu Z, Wu H, Zhu H, Wu X and Hait WN: Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res. 1:420–427. 2003.PubMed/NCBI
28	Liang Q, Xiong H, Gao G, et al: Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther. 4:759–762. 2005. View Article : Google Scholar : PubMed/NCBI
29	Tang Y, Nakada MT, Rafferty P, et al: Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res. 4:371–377. 2006. View Article : Google Scholar : PubMed/NCBI
30	Yan L, Zucker S and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
31	Aristizabal P, Graesslin O, Barranger E, et al: A suggested modification to FIGO stage I endometrial cancer. Gynecol Oncol. 133:192–196. 2014. View Article : Google Scholar : PubMed/NCBI
32	Aliagas E, Vidal A, Texidó L, et al: High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm. 2014:5090272014.PubMed/NCBI
33	Nakamura K, Kodama J, Hongo A and Hiramatsu Y: Role of emmprin in endometrial cancer. BMC Cancer. 12:1912012. View Article : Google Scholar : PubMed/NCBI
34	Ueda K, Yamada K, Urashima M, et al: Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol Rep. 17:731–735. 2007.PubMed/NCBI
35	Morris PC, Anderson JR, Anderson B and Buller RE: Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol. 56:406–411. 1995. View Article : Google Scholar : PubMed/NCBI
36	Thigpen JT, Brady MF, Alvarez RD, et al: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 17:1736–1744. 1999.PubMed/NCBI